Catalent Applied Drug Delivery Institute Partners with AAPS on 3rd Annual Global Academic Competition - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Catalent Applied Drug Delivery Institute Partners with AAPS on 3rd Annual Global Academic Competition
Competition seeks to encourage academic research and accelerate drug delivery applications.

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 2

Catalent Applied Drug Delivery Institute’s “3rd Annual Global Academic Competition for Life Science Leaders of Tomorrow,” in collaboration with the American Association of Pharmaceutical Scientists (AAPS) is now open for entries at www.drugdeliveryinstitute.com/global-academic-competition. The aim is to foster an interest in drug delivery among university students enrolled in pharmaceutical sciences, industrial pharmacy, drug delivery, drug development, or other related courses. Participating universities in the US include, St. John’s, Rutgers, New Jersey Institute of Technology, and University of North Carolina at Chapel Hill. In Europe, participating universities include Saarland and Düsseldorf, Germany and Bath and Bristol in the UK. /p>

Participants will compete for one of five prizes of $2,000, a complimentary, one-year AAPS membership, and the opportunity to have their submissions published by Catalent in the Institute and/or industry publications. Articles submitted should be original and based on topics such as drug development, improving therapeutic profiles and bioavailability, pre-formulation, drug delivery innovation in inhalation, biologics, lipid-based systems, crossing the blood-brain barrier, or on the delivery of drugs in certain patient groups such as pediatrics. The deadline for entries is March 28, 2014. More details on the competition, including entry forms and contest rules can be found here.

Source: Catalent Applied Drug Delivery Institute

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here